Obesity

Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments

13 days ago   |   By Journal of Biosciences

Abstract
Type II diabetes mellitus and obesity are two common pathophysiological conditions of metabolic syndrome , a collection of similar metabolic dysfunctions due to sedentary lifestyle and overnutrition. Obesity arises from improper adipogenesis which otherwise has a crucial role in maintaining proper metabolic functions. Downstream events arising from obesity have been linked to T2DM. The nuclear receptor peroxisome proliferator activator gamma , responsible for maintaining lipid and glucose homeostasis, is down-regulated under obesity leading to a weakened insulin sensitivity of the...
Read more ...

 


Search by Tags

   Obesity      Therapeutics      Clinical      Drug      Drugs  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow

Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow

Lucence, a genomic medicine company developing blood-based tests for cancer screening and treatment selection, announced this week the close of a $20 million Series A funding... Read more ...

Biopharma Execs Remain Optimistic Despite Political Headwinds

Biopharma Execs Remain Optimistic Despite Political Headwinds

Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. Nevertheless, senior figures remain... Read more ...

France-Based Tissium Boosts US Work After Closing €38.75M Series B

France-Based Tissium Boosts US Work After Closing €38.75M Series B

Tissium is targeting Boston's biotech scene to advance its platform of proprietary biopolymers after building out its manufacturing capabilities in France. Backed by a €38.75... Read more ...

A blight-free future

A blight-free future

Bond LSC scientist works with global consortium to eliminate costly rice disease Rice terraces in Sapa, Vietnam: Rice is the world's most important food plant, playing a vital... Read more ...

Small Scale Perception in Medical Body Area Networks

Small Scale Perception in Medical Body Area Networks

Dou Fan , Aifeng Ren , Nan Zhao , Daniyal Haider , Xiaodong Yang , Jie Tian Early Access Note: Early Access articles are new content made available in advance of the final... Read more ...

High Precision Digitization of Paper-Based ECG Records: A Step Toward...

High Precision Digitization of Paper-Based ECG Records: A Step Toward Machine Learning

Mohammed Baydoun , Lise Safatly , Ossama K. Abou Hassan , Hassan Ghaziri , Ali El Hajj , Hussain Isma'eel Early Access Note: Early Access articles are new content made... Read more ...

Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer

Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer

A drug candidate once shelved by Takeda Pharmaceutical has found new life within Roivant Sciences spinout Myovant as a potential once-daily oral hormone therapy for patients... Read more ...

Study Food Science in Spain

Study Food Science in Spain

Read more ...

USRG Application NOW OPEN

USRG Application NOW OPEN

UNDERGRADUATE SUMMER RESEARCH GRANT PROGRAM Roll up your sleeves. Become a researcher! Program dates: May 26, 2020 - July 31, 2020 Are you an undergraduate engineering student... Read more ...

Reata Rakes In $505M to Advance Development of Two Rare Disease Drugs

Reata Rakes In $505M to Advance Development of Two Rare Disease Drugs

Reata Pharmaceuticals on Tuesday closed a stock sale, raising $505.1 million to advance the company's two lead drug candidates to regulatory review. Reata's stock price jumped... Read more ...